← All stocks

KYNTRA BIO, INC.

KYNB Net selling
CIK 0000921299 #4913 in the set updated 18 Sep 2026
Bought (120 mo)
$1.64M
out of their own pocket, the only kind of buying there is
Sold (120 mo)
$192.36M
$1.06M on a plan · $150.68M straight out of an exercise
Sold at will
$40.62M
202 of 754 sales
Net
−$190.72M
−$38.98M against sales at will

By person

25 insiders · 802 transactions
0.2×

Thane Wettig holds only 0.2 times base salary in stock. $197.36K of shares against $665.00K in salary for 2025.

Salary from the company's own proxy. The shares are what Thane Wettig last reported holding, valued at $7.09, the price Common Stock was last bought or sold at on the open market here, on 14 May 2026.

Insider
Role
Bought
Sold
Net
Holding
Worth
Change
Neff Thomas B
Chief Executive Officer
$121.79M (438) scheduled
−$121.79M
5,238,123
$37.14M
−17.9%
Cotroneo Pat
Executive Advisor & Former CFO
$22.65M (52) scheduled
−$22.65M
274,536
$1.95M
+64.2%
Yu K Peony
Chief Medical Officer
$12.37M (37) scheduled
−$12.37M
192,292
$1.36M
−8.7%
Kurkijarvi Kalevi
Director
$8.05M (56) scheduled
−$8.05M
37,800
$268.00K
−30.0%
Chung Christine
SVP, CHINA OPERATIONS
$5.82M (51) scheduled
−$5.82M
294,903
$2.09M
+87.7%
RIGGS RORY B
Director
$4.75M (7)
−$4.75M
1,001,463
$7.10M
−7.7%
KEARNS THOMAS F JR
Director
$3.92M (8) scheduled
−$3.92M
249,764
$1.77M
+1.7%
Routti Jorma
Director
$3.82M (19) scheduled
−$3.82M
161,540
$1.15M
+26.4%
Tamura Toshinari
Director
$2.88M (5) scheduled
−$2.88M
56,400
$399.88K
+17.5%
Rosenkranz Roberto Pedro
Director
$1.33M (20) scheduled
−$1.33M
96,100
$681.35K
+128.8%
Schoeneck James A
Director
$224.52K (3)
$1.42M (10) scheduled
−$1.20M
139,854
$991.56K
Eisner Mark
EVP, Chief Medical Officer
$614.32K (7)
−$614.32K
159,917
$1.13M
Conterno Enrique A
Chief Executive Officer
$988.88K (2)
$1.42M (9)
−$435.26K
402,522
$2.85M
+6,776%
Graham Juan
CHIEF FINANCIAL OFFICER
$305.22K (10)
−$305.22K
164,863
$1.17M
+11,676%
Lema Gerald
Director
$163.45K (1)
+$163.45K
40,666
$288.32K
Ho Maykin
Director
$148.59K (2) scheduled
−$148.59K
31,501
$223.34K
Blaug Suzanne
Director
$146.57K (2) scheduled
−$146.57K
29,594
$209.82K
EDWARDS JEFFREY L
Director
$135.62K (2) scheduled
−$135.62K
33,977
$240.90K
Henderson Jeffrey William
Director
$133.45K (5) scheduled
−$133.45K
28,866
$204.66K
Wettig Thane
CEO
$235.48K (6)
$365.02K (9)
−$129.54K
27,836
$197.36K
Kouchakji Elias
SVP, Clinical Dev, Drug Safety
$129.29K (1)
−$129.29K
147,346
$1.04M
+49.1%
Brennan Aoife
Director
$81.37K (2) scheduled
−$81.37K
27,947
$198.14K
Cravatt Benjamin
Director
$67.72K (2) scheduled
−$67.72K
28,736
$203.74K
Adib Deyaa
Chief Medical Officer
$25.88K (1)
+$25.88K
82,123
$582.25K
+36.9%
DeLucia David
Chief Financial Officer
4,355
$30.88K
−37.5%

No percentages here. This company's share count has moved by a factor of 25.0 over the window, from 4,043,899 to 101,043,970 shares. A split, a merger or a large issue changes what the company is, and a holding measured at one point in that run is not a fraction of it at another.

Insider
Date
Role
Action
Shares
Price
Amount
Wettig Thane
14 May 2026
CEO
Buy
2,800
$7.09
$19.85K
Wettig Thane
17 Nov 2025
CEO
Buy
2,700
$9.10
$24.57K
Wettig Thane
13 Nov 2025
CEO
Buy
1,000
$9.18
$9.18K
Schoeneck James A
30 Jun 2025
Director
Buy indirect
23,567
$5.07
$119.48K
Wettig Thane
24 Mar 2025
CEO
Buy
145,000
$0.35
$50.66K
Schoeneck James A
21 Mar 2025
Director
Buy indirect
50,000
$0.34
$17.04K
Schoeneck James A
20 Mar 2025
Director
Buy indirect
250,000
$0.35
$88.00K
Adib Deyaa
12 Jun 2024
Chief Medical Officer
Buy
22,123
$1.17
$25.88K
Wettig Thane
7 Mar 2024
CEO
Buy
50,000
$1.91
$95.47K
Wettig Thane
26 Aug 2021
Chief Commercial Officer
Buy
3,100
$11.53
$35.74K
Conterno Enrique A
11 Jun 2020
Chief Executive Officer
Buy indirect
19,800
$35.28
$698.60K
Conterno Enrique A
10 Jun 2020
Chief Executive Officer
Buy indirect
8,000
$36.29
$290.28K
Showing 250 of 802 transactions. The figures above use every one of them.

What was left out

Form 4 filings counted 558
Amendments (4/A) skipped 8
Filings about a different issuer 0
Unreadable filings 0
Joint filings 0
Sales on a Rule 10b5-1 plan 19
Sales straight out of an exercise 533
Sales at will 202
Transactions with no price 0
Shares from compensation/vesting 6,551,787
Sales filed before the plan box existed 185
History held since 2 Sep 2016